Berardino De Bari

Berardino De Bari

Auto-generated profile, based on publicly available information

Berardino De Bari

Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois, CHUV, 46 rue du Bugnon, 1011, Lausanne, Switzerland.

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Radiotherapy and Oncology
Verified
Journal Article
Open access
CSCarl Salembier
Carl Salembier
GVGeert Villeirs
Geert Villeirs
BBBerardino De Bari
Berardino De Bari
PHPeter Hoskin
Peter Hoskin
BPBradley R. Pieters
Bradley R. Pieters
VFValérie Fonteyne
Valérie Fonteyne
Delineation of clinical target volumes (CTVs) remains a weak link in radiation therapy (RT), and large inter-observer variation is seen. Guidelines for target and organs at risk delineation for prostate cancer in the primary setting are scarce. The aim was to develop a delineation guideline obtained by consensus between a broad European group of radiation oncologists. An ESTRO contouring consensus panel consisting of leading radiation oncologists and one radiologist with known subspecialty expertise in prostate cancer was asked to delineate the prostate, seminal vesicles and rectum on co-registered CT and MRI scans. After evaluation of the different contours, literature review and multiple informal discussions by electronic mail a CTV definition was defined and a guide for contouring the CTV of the prostate and the rectum was developed. The panel achieved consensus CTV contouring definitions to be used as guideline for primary RT of localized prostate cancer. The ESTRO consensus on CT/MRI based CTV delineation for primary RT of localized prostate cancer, endorsed by a broad base of the radiation oncology community, is presented to improve consistency and reliability.

30 June 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
SSSebastien Salas
Sebastien Salas
NRN. Resseguier
N. Resseguier
JBJ. Y. Blay
J. Y. Blay
ACA. Le Cesne
A. Le Cesne
AIA. Italiano
A. Italiano
CBC. Bouvier
C. Bouvier
Solitary fibrous tumors (SFT) are rare unusual ubiquitous soft tissue tumors that are presumed to be of fibroblastic differentiation. At present, the challenge is to establish accurate prognostic factors. A total of 214 consecutive patients with SFT diagnosed in 24 participating cancer centers were entered into the European database (www.conticabase.org) to perform univariate and multivariate analysis for overall survival (OS), local recurrence incidence (LRI) and metastatic recurrence incidence (MRI) by taking competing risks into account. A prognostic model was constructed for LRI and MRI. Internal and external validations of the prognostic models were carried out. An individual risk calculator was carried out to quantify the risk of both local and metastatic recurrence. We restricted our analysis to 162 patients with local disease. Twenty patients (12.3%) were deceased at the time of analysis and the median OS was not reached. The LRI rates at 10 and 20 years were 19.2% and 38.6%, respectively. The MRI rates at 10 and 20 years were 31.4% and 49.8%, respectively. Multivariate analysis retained age and mitotic count tended to significance for predicting OS. The factors influencing LRI were viscera localization, radiotherapy and age. Mitotic count, tumor localization other than limb and age had independent values for MRI. Three prognostic groups for OS were defined based on the number of unfavorable prognostic factors and calculations were carried out to predict the risk of local and metastatic recurrence for individual patients. LRI and MRI rates increased between 10 and 20 years so relapses were delayed, suggesting that long-term monitoring is useful. This study also shows that different prognostic SFT sub-groups could benefit from different therapeutic strategies and that use of a survival calculator could become standard practice in SFTs to individualize treatment based on the clinical situation.

3 October 2018 in Acta Oncologica
Verified
Journal Article
Closed access
JCJ. Castelli
J. Castelli
ASA. Simon
A. Simon
CLC. Lafond
C. Lafond
NPN. Perichon
N. Perichon
BRB. Rigaud
B. Rigaud
RCR. de Crevoisier
R. de Crevoisier
Large anatomical variations can be observed during the treatment course intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC), leading to potential dose variations. Adaptive radiotherapy (ART) uses one or several replanning sessions to correct these variations and thus optimize the delivered dose distribution to the daily anatomy of the patient. This review, which is focused on ART in the HNC, aims to identify the various strategies of ART and to estimate the dosimetric and clinical benefits of these strategies. We performed an electronic search of articles published in PubMed/MEDLINE and Science Direct from January 2005 to December 2016. Among a total of 134 articles assessed for eligibility, 29 articles were ultimately retained for the review. Eighteen studies evaluated dosimetric variations without ART, and 11 studies reported the benefits of ART. Eight in silico studies tested a number of replanning sessions, ranging from 1 to 6, aiming primarily to reduce the dose to the parotid glands. The optimal timing for replanning appears to be early during the first two weeks of treatment. Compared to standard IMRT, ART decreases the mean dose to the parotid gland from 0.6 to 6 Gy and the maximum dose to the spinal cord from 0.1 to 4 Gy while improving target coverage and homogeneity in most studies. Only five studies reported the clinical results of ART, and three of those studies included a non-randomized comparison with standard IMRT. These studies suggest a benefit of ART in regard to decreasing xerostomia, increasing quality of life, and increasing local control. Patients with the largest early anatomical and dose variations are the best candidates for ART. ART may decrease toxicity and improve local control for locally advanced HNC. However, randomized trials are necessary to demonstrate the benefit of ART before using the technique in routine practice.

1 December 2016 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
JCJ. Castelli
J. Castelli
BBB. De Bari
B. De Bari
ADAdrien Depeursinge
Adrien Depeursinge
ASA. Simon
A. Simon
ADA. Devillers
A. Devillers
Jean BourhisJean Bourhis
Jean Bourhis

1 December 2013 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
Filippo AlongiFilippo Alongi
Filippo Alongi
BBBerardino De Bari
Berardino De Bari
FCFranco Campostrini
Franco Campostrini
SAStefano Arcangeli
Stefano Arcangeli
DMDeliu Victor Matei
Deliu Victor Matei
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa

1 July 2014 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JEJesper Grau Eriksen
Jesper Grau Eriksen
CSCarl Salembier
Carl Salembier
SRSofia Rivera
Sofia Rivera
BBBerardino De Bari
Berardino De Bari
DBDaniel Berger
Daniel Berger
VVVincenzo Valentini
Vincenzo Valentini